ATORX — Alligator Bioscience AB Cashflow Statement
0.000.00%
- SEK122.19m
- SEK127.84m
- SEK57.77m
Annual cashflow statement for Alligator Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -144 | -142 | -193 | -249 | -229 |
| Depreciation | |||||
| Non-Cash Items | 0.042 | 0.069 | 0.08 | 0.073 | -0.011 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -8.62 | 3.32 | 8.34 | 49.1 | -32 |
| Change in Accounts Receivable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -141 | -127 | -173 | -189 | -212 |
| Capital Expenditures | -0.102 | -0.045 | -0.44 | -2.46 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 157 | 0 | — | 0 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 157 | -0.045 | -0.44 | -2.46 | 0 |
| Financing Cash Flow Items | — | -33.9 | -0.343 | -24.1 | -14.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -6.15 | 302 | -7.83 | 162 | 211 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.53 | 175 | -181 | -31.2 | -1.81 |